CoChat

Targeted Naltrexone for Early Problem Drinkers

Kranzler, Henry R., Armeli, Stephen, Tennen, Howard, Blomqvist, Ola, Oncken, Cheryl, Petry, Nancy, Feinn, Richard · 2003 · Journal of Clinical Psychopharmacology
Cited by 97

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Most published studies of the efficacy of naltrexone for alcohol treatment have focused on daily medication for relapse prevention among abstinent alcoholics. The present study compared the effects of naltrexone with those of placebo in a sample of early problem drinkers who received study medication either daily or targeted to situations identified by the patients as being high risk for heavy drinking. Patients (n = 153; 58% male) were randomly assigned to receive naltrexone (50 mg) or placebo on a daily or targeted basis, yielding comparable numbers of patients in each of four treatment groups. Patients were trained to use structured nightly diaries in which they recorded their alcohol consumption and medication intake. Analysis was conducted with hierarchical linear modeling. Irrespective of whether they received naltrexone or placebo, patients in the targeted condition showed a reduced likelihood of any drinking. There was a reduced likelihood of heavy drinking, both for patients who received naltrexone and for patients who were in the targeted groups (either naltrexone or placebo), although these effects diminished as the number of tablets available to the targeted groups was reduced over the 8-week treatment period. Although the effect was a modest one, daily naltrexone reduced the risk of heavy drinking in this patient group. Furthermore, use of a targeted approach to medication treatment appears to be a useful strategy for reducing both drinking and heavy drinking. Efforts to replicate these findings are warranted, since they suggest that schedules of medication administration other than daily should be evaluated for treatment of problem drinking.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.jcp.0000084030.22282.6d

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 97

Metadata

Authors
Kranzler, H. R., Armeli, S., Tennen, H., Blomqvist, O., Oncken, C., Petry, N., & Feinn, R.
Venue
Journal of Clinical Psychopharmacology
Published
2003-06
Volume
23
Issue
3
Pages
294-304
ISSN
0271-0749 (ISSN-L)
OpenAlex
W1995418042
Cited by
97
References
7
FWCI
6.28
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeted Naltrexone for Early Problem Drinkers. https://app.cochat.ai/papers/10.1097/01.jcp.0000084030.22282.6d
The paper
Kranzler, H. R., Armeli, S., Tennen, H., Blomqvist, O., Oncken, C., Petry, N., & Feinn, R. (2003). Targeted Naltrexone for Early Problem Drinkers. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/01.jcp.0000084030.22282.6d

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.